Physician profile
Peter J Miceli
NPI 1487701777
$1,558.05
in general payments reported to CMS, 2019-2025
14 companies · $491 in 2025
The $491 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.28 · 2020: $83.55 · 2021: $48.59 · 2022: $189 · 2023: $511 · 2024: $191 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,193.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $840.70 | 2019-2025 | |
| Genzyme Corporation | $149.82 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $124.33 | 2025 | Dupixent |
| Stryker Corporation | $110.90 | 2022 | |
| Integra Lifesciences Corporation | $80.18 | 2025 | Relieva Spinplus Nav, Inspira Air, Acclarent Aera |
| Medtronic, INC. | $63.66 | 2025 | Propel |
| Hikma Pharmaceuticals USA | $62.30 | 2022-2024 | Ryaltris |
| Neurent Medical Limited | $25.08 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Paratek Pharmaceuticals, INC. | $23.26 | 2025 | Xhance |
| Arbor Pharmaceuticals, INC. | $20.62 | 2019 | |
| Alk-Abello, INC | $14.96 | 2023 | Odactra, Ragwitek, Grastek |
| Smith+Nephew, INC. | $14.80 | 2025 | Tula |
| Merck Sharp & Dohme LLC | $14.48 | 2023 | |
| Pfizer INC. | $12.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Miceli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.